Abstract. Heat shock protein 105 (HSP105) is overexpressed in various tumors and is known to protect cells from cytotoxic stimuli. The prognostic significance of HSP105 expression in cancer has not been fully evaluated. Here, HSP105 expression in lung adenocarcinoma was immunohistochemically examined in 116 patients: 68 males and 48 females with ages ranging from 38-81 (median 63) years. Tumor stage was I in 64, II in 16 and III in 36 patients. In non-cancerous tissues, HSP105 was expressed in the ciliated cells of bronchi. Tumor cells were constantly positive for HSP105, with varying intensities. The HSP105 score in each case was determined based on the staining intensity of the tumor cells occupying the widest area of cancerous tissue as follows: cases with tumor cells showing an intensity weaker than, comparable to and stronger than the bronchial epithelium were assigned a score of 1, 2 and 3, and numbered 84, 19 and 13 cases, respectively. HSP105 score was significantly correlated with the rate of recurrence and the stage of the disease. Univariate analysis showed that lymph node metastasis, disease stage and HSP105 score were unfavorable prognostic factors. Multivariate analysis revealed that lymph node metastasis and HSP105 score were independent prognostic factors for overall and disease-free survival. HSP105 expression is useful for the prediction of prognosis in patients with lung adenocarcinoma.
Introduction
Since 1985, lung cancer has been the most common cause of cancer-related death worldwide, with an annual worldwide mortality of 1.18 million in 2002 (1) . Non-small cell lung cancer (NSCLC) comprises 75-85% of all lung cancers, with approximately two-thirds of NSCLC patients being diagnosed at an advanced stage. Despite advances in the methods of detection and treatment of lung cancer, the prognosis for NSCLC patients remains unfavorable. The establishment of effective therapeutic modalities is essential to improving this prognosis. Previous studies have provided information related to the factors influencing patient prognosis in NSCLC. These include clinical, pathological and molecular factors.
Heat shock protein 105 (HSP105) is a stress protein belonging to the HSP105/110 family, and plays a role in protecting cells from cytotoxic effects such as serum depletion, heat shock and the addition of hydrogen peroxide (2) (3) (4) (5) (6) . HSP105 might contribute to the survival of cancer cells, which usually withstand cytotoxic environments such as severe hypoxia, high temperatures and the administration of doxorubicin. Recently, Hosaka et al (13) reported that the knock-down of HSP105 induces apoptosis in cancer cell lines in a caspase-dependent manner, suggesting a correlation between HSP105 expression and prognosis in cancer patients. Various types of malignant tumors, such as colorectal, pancreatic, thyroid, esophageal, breast and bladder cancers, are known to overexpress HSP107 (7). Recently, HSP105 was proposed as a useful target in cancer immunotherapy (8) . Using tissue microarray, Ullmann et al evaluated the correlation of protein expression in cancer cells with the prognosis of 75 patients with lung adenocarcinoma, and found the expression of HSP together with cathepsin E to be prognostic markers, as revealed by univariate analysis (9) . However, the staining intensity of cancer cells was arbitrarily evaluated. Here, to further evaluate the prognostic significance of HSP105 expression, immunohistochemical analysis was preformed in 116 lung adenocarcinomas. We found that the normal bronchial epithelium expressed HSP105. The staining intensity of HSP105 in cancer cells was determined by a comparison with its intensity in the bronchial epithelium, and the significance of HSP105 as an independent factor for the prediction of prognosis was evaluated by multivariate analysis. Table I . Characteristics of the 116 patients with pulmonary adenocarcinoma. Immunohistochemistry. An immunoperoxidase procedure was performed on the paraffin-embedded sections using the standard avidin-biotin-peroxidase complex method. After antigen retrieval with a Pascal pressurized heating chamber (Dako A/S, Glostrup, Denmark), the sections were incubated with anti-HSP105 (Novocastra, Newcastle, UK; dilution; 1:100), anti-active caspase 3 (Abcam Ltd., Cambridge, UK; 1:100) or anti-Ki-67 antibody (Dako; 1:100). As the negative control, staining was carried out in the absence of primary antibody. Staining of the bronchial epithelium was used as the internal positive control for HSP105. The HSP105 score in each case was determined based on the staining intensity of the tumor cells occupying the widest area of cancerous tissue as follows: cases with tumor cells showing an intensity weaker than, comparable to, and stronger than the bronchial epithelium were assigned a score of 1, 2 and 3, respectively (Fig. 1A-D) . The apoptosis index was determined by evaluating the proportion of active caspase 3-positive tumor cells. Cases in which >3% of tumor cells were active caspase 3-positive were categorized as having a high apoptosis index. Proliferation of tumor cells was evaluated by Ki-67 labeling. Cases in which >3% of tumor cells were Ki-67-positive were categorized as having a high proliferation index. Immunohistochemically-stained sections were evaluated independently by two investigators (T.O. and E.M). For patients with discrepant findings, the results were compared and discussed.
Materials and methods

Patients
Statistical analysis. All statistical analysis was performed using StatView software (SAS Institute Inc., Cary, NC). Five-year overall survival (OS) and disease-free survival (DFS) were calculated by the Kaplan-Meier method, and differences in survival curves were analyzed by the log-rank test. Independent prognostic factors were analyzed by the Cox's proportional hazard regression model. The presence of a statistically significant difference was denoted by P<0.05.
Results
Clinical findings. The clinical findings are summarized in Table I . There were 68 males and 48 females with ages ranging from 38 to 81 (median 63) years. The size of the main tumor ranged from 8 to 70 (median 30.5) mm. Tumor stage was I in 64 , II in 16 and III in 36 patients. Tumor recurrence was found in 55 cases, with the interval from surgery ranging from 2.5 to 78.7 (median 13.2) months. Five-year OS in all patients and in patients with stage I, II and III tumors was 69.5, 82.6, 57.6 and 47.3%, respectively (Fig. 2) . DFS in all patients and in patients with stage I, II and III tumors was 51.5, 80.9, 59.1 and 36.5%, respectively (Fig. 3A and B) . Table III . Univariate and multivariate analysis of prognostic factors for overall and disease-free survival.
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wall and lumen, but not in alveolar epithelial cells in noncarcinomatous areas (Fig. 1A) . Tumor cells were constantly positive for HSP105, but with varying expression levels. The HSP105 expression level in each case was classified based on the staining intensity of the tumor cells occupying the widest area of cancerous tissue as follows: cases with tumor cells showing an intensity weaker than, comparable to, and stronger than the bronchial epithelium were assigned a score of 1, 2 and 3, respectively (Fig. 1A-D) . Among 116 patients, 84 were assigned a score of 1, 19 a score of 2 and 13 a score of 3.
The correlation of HSP105 score with clinical features is shown in Table II . ¯2 analysis revealed T category, disease stage, tumor recurrence and a low apoptosis index to be significantly correlated with a high HSP105 score. Patients with score 1 and score 2 tumors had a significantly improved OS than those with score 3 tumors (P<0.0001 and P=0.016, respectively) (Fig. 3A) . Patients with score 1 and score 2 tumors had a significantly longer DFS than those with score 3 tumors (P<0.0001 and P=0.032, respectively) (Fig. 3B) .
Univariate analysis revealed lymph node metastasis, advanced stage and high HSP105 score to be significant unfavorable factors for both 5-year OS and DFS (Table III) . Multivariate analysis revealed that lymph node metastasis and HSP105 score were independent prognostic factors of both 5-year OS and DFS (Table III) .
Discussion
Patient characteristics such as gender, age and 5-year OS were similar in the present study to those of previous reports (11) . Moreover, the results of univariate and multivariate analysis regarding the prognostic significance of clinicopathological factors, such as lymph node metastasis and stage of disease, were also in accordance with previous studies. These findings indicate that the results obtained from the present cases are commonly applicable.
Among the clinicopathological factors examined, high HSP105 expression was related to advanced disease stage, high T category, a low apoptosis index and a high probability of recurrence. A low apoptosis rate may explain the larger size and higher recurrence rate of tumors with a high HSP105 score compared to those with a low score. Since HSP105 expression was not correlated with N category, HSP105 might not affect the metastatic potential of lung adenocarcinoma.
The present findings in 116 cases with lung adenocarcinoma, that patients with score 1 and score 2 tumors exhibit significantly longer OS and DFS than those with score 3 tumors, are in agreement with those reported by Ullmann et al (9) , who found survival time to be longer in patients with low HSP105 expression in a study of 75 cases. Using multivariate analysis, we further demonstrated that HSP105 expression is an independent prognostic factor for OS and DFS.
The neuronal cell line PC12 stably overexpressing HSP105 exhibited resistance to caspase-mediated apoptosis (12) . In addition, the knock-down expression of HSP105 induced apoptosis in a caspase 3-dependent manner in the colon cancer cell line HCT116. Consistent with these reports, high expression of HSP105 was inversely correlated with active caspase 3 positivity in clinical samples of lung adenocarcinoma. These findings indicate that the caspase-mediated apoptosis of tumor cells could be suppressed by the overexpression of HSP105. This might explain why the prognosis for patients having tumors with a high HSP105 score is less favorable than that of patients having tumors with a low score.
According to studies by Hatayama et al (12) and Hosaka et al (13) , overexpression of HSP105 did not affect the growth rate of the neuronal cell line PC12 and fibroblast cell line NIH/3T3. Indeed, no correlation was found between HSP105 expression and the proliferation index in the clinical samples of the present study. Rather than increasing proliferative activity, HSP105 appeared to exert an anti-apoptotic effect.
Although the overexpression of HSP105 has been demonstrated in various types of tumors, the significance of HSP105 as a prognostic factor has only been studied in lung adenocarcinoma. Further studies are necessary to determine whether HSP105 expression is a useful marker for the prediction of prognosis in other types of cancer.
